Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  AB Science    AB   FR0010557264

AB SCIENCE

(AB)
  Report
 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Paris
02/17/2020 02/18/2020 02/19/2020 02/20/2020 02/21/2020 Date
8.22(c) 8.4(c) 8.04(c) 8(c) 9.45(c) Last
87 246 260 142 173 643 146 287 1 319 476 Volume
-2.49% +2.19% -4.29% -0.50% +18.13% Change
More quotes
Financials (EUR)
Sales 2019 1,50 M
EBIT 2019 -
Net income 2019 -
Debt 2019 -
Yield 2019 -
Sales 2020 1,40 M
EBIT 2020 -
Net income 2020 -
Debt 2020 -
Yield 2020 -
P/E ratio 2019 -
P/E ratio 2020 -
Capi. / Sales2019 278x
Capi. / Sales2020 297x
Capitalization 416 M
More Financials
Company
AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals. 
Sector
Pharmaceuticals
Calendar
05/04Earnings Release
More about the company
Latest news on AB SCIENCE
02/20AB Science announces positive top-line Phase 2B/3 results for oral masitinib ..
GL
01/08AB SCIENCE : announces that FDA green-lights U.S. patient enrollment in masitini..
AQ
2019AB Science announces the publication of new results in the peer-reviewed jour..
GL
2019SCIENCE : AB Science announces the publication of new results in the peer-review..
GL
2019SCIENCE : AB Science announces publication of three AB8939 scientific abstracts ..
GL
2019AB Science announces publication of three AB8939 scientific abstracts in the ..
GL
2019AB SCIENCE : announces publication of three AB8939 scientific abstracts in the s..
AQ
2019AB Science provides the summary of webcast with Key Opinion Leaders on masiti..
GL
2019SCIENCE : Webconference presentation on masitinib in mastocytosis
PU
2019SCIENCE : AB Science will host a live webcast on masitinib in severe asthma on M..
GL
2019AB SCIENCE : will host a live webcast on masitinib in severe asthma on December..
AQ
2019AB Science will host a live webcast on masitinib in severe asthma on Decembe..
GL
2019SCIENCE : AB Science will host a live webcast on masitinib in severe asthma on D..
GL
2019AB SCIENCE : provides the summary of webcast with Key Opinion Leaders on Indolen..
AQ
2019AB Science provides clarification regarding the article published yesterday i..
GL
More news
News in other languages on AB SCIENCE
02/21AB SCIENCE : plus forte hausse du SRD à la clôture du vendredi 21 février 2020
02/21AB SCIENCE : plus forte hausse du SRD à la mi-séance du vendredi 21 février 2020
02/21AB SCIENCE : bondit de 25% après une étude encourageante sur la SEP
02/21EN DIRECT DES MARCHES : Engie, Valeo, Genfit, ADP, Teleperformance, Unicredit..
02/21BIOTECH TIME : Genfit s'en serait bien passé, AB Science s'en réjouit
More news
Analyst Recommendations on AB SCIENCE
More recommendations
Sector news : Specialty & Advanced Pharmaceuticals
02/21Marriott Hires Former Merck CIO as Tech Chief
DJ
02/21Pharmaceutical companies develop system to better track counterfeit drugs
RE
02/21DAVIDSON KEMPNER CAPITAL MANAGEMENT : Form 8.3 - Allergan Plc
DJ
02/21ALLERGAN : Form 8.3 -
DJ
02/21ABBVIE : Form 8.3 -
DJ
More sector news : Specialty & Advanced Pharmaceuticals
Chart AB SCIENCE
Duration : Period :
AB Science Technical Analysis Chart | AB | FR0010557264 | MarketScreener
Technical analysis trends AB SCIENCE
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Average target price 10,00  €
Last Close Price 9,45  €
Spread / Highest target 5,82%
Spread / Average Target 5,82%
Spread / Lowest Target 5,82%
EPS Revisions
Managers
NameTitle
Alain Moussy Chairman, CEO & Scientific Director
Laurent Guy Chief Financial Officer
Christian Fassotte Global Chief Medical Officer
Antonello Cervone Director-Information Technology
Edita Dolimier Head-Clinical Development
Sector and Competitors
1st jan.Capitalization (M$)
AB SCIENCE75.65%380
MERCK KGAA17.75%57 597
KYOWA KIRIN CO., LTD.-1.06%12 999
ZHANGZHOU PIENTZEHUANG PHARMACEUTICAL., LTD15.04%10 731
JAZZ PHARMACEUTICALS PLC-9.69%7 666
BETTA PHARMACEUTICALS CO LTD--.--%4 711